Adela Wu1, Beatrice Ugiliweneza2, Dengzhi Wang2, Gary Hsin3, Maxwell Boakye2, Stephen Skirboll1. 1. Department of Neurosurgery, Stanford University, Palo Alto, California, USA. 2. Department of Neurological Surgery, University of Louisville School of Medicine, Louisville, Kentucky, USA. 3. Department of Extended Care and Palliative Medicine Service, VA Palo Alto Health Care System, Palo Alto, California, USA.
Abstract
Background: Glioblastoma (GBM) carries a poor prognosis despite standard of care. Early palliative care (PC) has been shown to enhance survival and quality of life while reducing healthcare costs for other cancers. This study investigates differences in PC timing on outcomes for patients with GBM. Methods: This study used Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 1997 to 2016. Based on ICD codes, three groups were defined: (1) early PC within 10 weeks of diagnosis, (2) late PC, and (3) no PC. Outcomes were compared between the three groups. Results: Out of 10 812 patients with GBM, 1648 (15.24%) patients had PC consultation with an overall positive trend over time. There were no significant differences in patient characteristics. The late PC group had significantly higher number of hospice claims (1.06 ± 0.69) compared to those without PC, in the last month of life. There were significant differences in survival among the three groups (P < .0001), with late PC patients with the longest mean time to death from diagnosis (11.72 ± 13.20 months). Conclusion: We present the first investigation of PC consultation prevalence and outcomes, stratified by early versus late timing, for adult GBM patients. Despite an overall increase in PC consultations, only a minority of GBM patients receive PC. Patients with late PC had the longest survival times and had greater hospice use in the last month of life compared to other subgroups. Prospective studies can provide additional valuable information about this unique population of patients with GBM. Published by Oxford University Press 2022.
Background: Glioblastoma (GBM) carries a poor prognosis despite standard of care. Early palliative care (PC) has been shown to enhance survival and quality of life while reducing healthcare costs for other cancers. This study investigates differences in PC timing on outcomes for patients with GBM. Methods: This study used Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 1997 to 2016. Based on ICD codes, three groups were defined: (1) early PC within 10 weeks of diagnosis, (2) late PC, and (3) no PC. Outcomes were compared between the three groups. Results: Out of 10 812 patients with GBM, 1648 (15.24%) patients had PC consultation with an overall positive trend over time. There were no significant differences in patient characteristics. The late PC group had significantly higher number of hospice claims (1.06 ± 0.69) compared to those without PC, in the last month of life. There were significant differences in survival among the three groups (P < .0001), with late PC patients with the longest mean time to death from diagnosis (11.72 ± 13.20 months). Conclusion: We present the first investigation of PC consultation prevalence and outcomes, stratified by early versus late timing, for adult GBM patients. Despite an overall increase in PC consultations, only a minority of GBM patients receive PC. Patients with late PC had the longest survival times and had greater hospice use in the last month of life compared to other subgroups. Prospective studies can provide additional valuable information about this unique population of patients with GBM. Published by Oxford University Press 2022.
Authors: J Nicholas Dionne-Odom; Andres Azuero; Kathleen D Lyons; Jay G Hull; Tor Tosteson; Zhigang Li; Zhongze Li; Jennifer Frost; Konstantin H Dragnev; Imatullah Akyar; Mark T Hegel; Marie A Bakitas Journal: J Clin Oncol Date: 2015-03-23 Impact factor: 44.544
Authors: Marie A Bakitas; Tor D Tosteson; Zhigang Li; Kathleen D Lyons; Jay G Hull; Zhongze Li; J Nicholas Dionne-Odom; Jennifer Frost; Konstantin H Dragnev; Mark T Hegel; Andres Azuero; Tim A Ahles Journal: J Clin Oncol Date: 2015-03-23 Impact factor: 44.544
Authors: Roger Stupp; Pierre-Yves Dietrich; Sandrine Ostermann Kraljevic; Alessia Pica; Ivan Maillard; Phillipe Maeder; Reto Meuli; Robert Janzer; Gianpaolo Pizzolato; Raymond Miralbell; François Porchet; Luca Regli; Nicolas de Tribolet; René O Mirimanoff; Serge Leyvraz Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: Jennifer S Temel; Joseph A Greer; Areej El-Jawahri; William F Pirl; Elyse R Park; Vicki A Jackson; Anthony L Back; Mihir Kamdar; Juliet Jacobsen; Eva H Chittenden; Simone P Rinaldi; Emily R Gallagher; Justin R Eusebio; Zhigang Li; Alona Muzikansky; David P Ryan Journal: J Clin Oncol Date: 2016-12-28 Impact factor: 44.544
Authors: Louis Burt Nabors; Jana Portnow; Manmeet Ahluwalia; Joachim Baehring; Henry Brem; Steven Brem; Nicholas Butowski; Jian L Campian; Stephen W Clark; Andrew J Fabiano; Peter Forsyth; Jona Hattangadi-Gluth; Matthias Holdhoff; Craig Horbinski; Larry Junck; Thomas Kaley; Priya Kumthekar; Jay S Loeffler; Maciej M Mrugala; Seema Nagpal; Manjari Pandey; Ian Parney; Katherine Peters; Vinay K Puduvalli; Ian Robins; Jason Rockhill; Chad Rusthoven; Nicole Shonka; Dennis C Shrieve; Lode J Swinnen; Stephanie Weiss; Patrick Yung Wen; Nicole E Willmarth; Mary Anne Bergman; Susan D Darlow Journal: J Natl Compr Canc Netw Date: 2020-11-02 Impact factor: 11.908